en.Wedoany.com Reported - Haleon is investing £175 million ($240 million) in India to build a greenfield manufacturing plant in Madhya Pradesh, expanding its presence in one of its fastest-growing markets and strengthening its Asian supply chain.
The British multinational consumer healthcare company aims to meet market demand projected to exceed £23 billion ($29 billion) by 2030. Haleon stated that India is central to its goal of reaching one billion new consumers globally by the same year.
Haleon owns brands such as Sensodyne, Panadol, and Advil. The new oral health manufacturing facility will be located in Madhya Pradesh, central India, near several technical colleges. This project is part of Haleon's "Win as One" strategy, which focuses on unlocking growth through improved productivity and cultural transformation within the company.
The plant will support supply across the Asian continent and enhance distribution capabilities in the domestic Indian market, allowing Haleon to reduce reliance on imports and shorten delivery times. According to Haleon, in-house supply chain capabilities will enable the company to respond to evolving consumer demands and market trends. The facility is expected to create up to 500 jobs and support local capacity and economic development.
India is one of Haleon's largest oral health markets. However, access to dental care remains limited in rural areas, where approximately 65% of the population lives. Haleon is launching low-cost and smaller-packaged toothpaste products to improve accessibility, including a 20-rupee ($0.21) Sensodyne pack for distribution across towns and villages. Over the past 12 months, the company has recruited more than 500 people for its sales team and invested in "last-mile" capabilities, increasing the number of motorcycle frontline teams. These drivers deliver test kits, samples, and diagnostic tools to rural areas that cannot be reached by retail stores and pharmacies.
Haleon operates mobile oral health awareness vans to reach rural communities, serving as community hubs for oral health education, health check-ups, and immediate product access.
Brian McNamara, CEO of Haleon, said: "India is a key strategic market for Haleon and a vital driver of our long-term growth. This investment strengthens our local manufacturing footprint and expands our reach in one of the world's fastest-growing consumer health markets. By increasing access to our trusted brands and building local capabilities, we are well-positioned to seize significant future opportunities. Our goal is to provide better everyday health for over 300 million additional consumers in India. This will be key to achieving our broader ambition of reaching one billion new consumers globally by 2030."
The new manufacturing plant is scheduled to open in early 2028, with supply from the facility expected to begin in 2029. This investment reflects Haleon's assessment that the Indian consumer health market will grow significantly over the next six years. According to Haleon, the combination of local production and enhanced distribution could enable the company to serve an additional 300 million Indian consumers.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
